Ranibizumab - Latest Advances

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Journal: BMJ open

Published: October 08, 2025

Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes.

Journal: Translational vision science & technology

Published: October 03, 2025

Presentation of post intravitreal anti-Vascular Endothelial Growth Factor (ranibizumab) endophthalmitis as frosted branch angiitis.

Journal: Retinal cases & brief reports

Published: October 03, 2025

Early Fluctuations of Exudative Lesions as Predictors of Two-Year Clinical Outcomes in Neovascular Age-Related Macular Degeneration.

Journal: Translational vision science & technology

Published: October 01, 2025

Endogenous Aspergillus endophthalmitis complicated by florid retinal neovascularization: double trouble.

Journal: Retinal cases & brief reports

Published: September 29, 2025

Blepharoptosis After Intravitreal Anti-VEGF Injections: A Prospective Study.

Journal: Ophthalmic plastic and reconstructive surgery

Published: September 29, 2025

Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab: A case report.

Journal: Retinal cases & brief reports

Published: September 22, 2025

Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Published: September 18, 2025

Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.

Journal: Retina (Philadelphia, Pa.)

Published: September 09, 2025

Analysis of the current research status and trends in retinal vein occlusion based on bibliometrics

Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Published: September 08, 2025

Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.

Journal: Cureus

Published: September 05, 2025

Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.

Journal: Retina (Philadelphia, Pa.)

Published: September 03, 2025

Filters

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes.

Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes.

Presentation of post intravitreal anti-Vascular Endothelial Growth Factor (ranibizumab) endophthalmitis as frosted branch angiitis.

Presentation of post intravitreal anti-Vascular Endothelial Growth Factor (ranibizumab) endophthalmitis as frosted branch angiitis.

Early Fluctuations of Exudative Lesions as Predictors of Two-Year Clinical Outcomes in Neovascular Age-Related Macular Degeneration.

Early Fluctuations of Exudative Lesions as Predictors of Two-Year Clinical Outcomes in Neovascular Age-Related Macular Degeneration.

Endogenous Aspergillus endophthalmitis complicated by florid retinal neovascularization: double trouble.

Endogenous Aspergillus endophthalmitis complicated by florid retinal neovascularization: double trouble.

Blepharoptosis After Intravitreal Anti-VEGF Injections: A Prospective Study.

Blepharoptosis After Intravitreal Anti-VEGF Injections: A Prospective Study.

Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab: A case report.

Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab: A case report.

Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.

Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.

Analysis of the current research status and trends in retinal vein occlusion based on bibliometrics

Analysis of the current research status and trends in retinal vein occlusion based on bibliometrics

Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.

Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.

Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.

Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.